Premium
Nanoparticles and radiotracers: advances toward radionanomedicine
Author(s) -
Pratt Edwin C.,
Shaffer Travis M.,
Grimm Jan
Publication year - 2016
Publication title -
wiley interdisciplinary reviews: nanomedicine and nanobiotechnology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.175
H-Index - 72
eISSN - 1939-0041
pISSN - 1939-5116
DOI - 10.1002/wnan.1402
Subject(s) - positron emission tomography , spect imaging , medical physics , molecular imaging , single photon emission computed tomography , nanomedicine , nuclear medicine , preclinical imaging , medical imaging , medicine , in vivo , nanotechnology , materials science , nanoparticle , radiology , microbiology and biotechnology , biology
In this study, we cover the convergence of radiochemistry for imaging and therapy with advances in nanoparticle ( NP ) design for biomedical applications. We first explore NP properties relevant for therapy and theranostics and emphasize the need for biocompatibility. We then explore radionuclide‐imaging modalities such as positron emission tomography ( PET ), single‐photon emission computed tomography ( SPECT ), and Cerenkov luminescence ( CL ) with examples utilizing radiolabeled NP for imaging. PET and SPECT have served as diagnostic workhorses in the clinic, while preclinical NP design examples of multimodal imaging with radiotracers show promise in imaging and therapy. CL expands the types of radionuclides beyond PET and SPECT tracers to include high‐energy electrons (β − ) for imaging purposes. These advances in radionanomedicine will be discussed, showing the potential for radiolabeled NPs as theranostic agents. WIREs Nanomed Nanobiotechnol 2016, 8:872–890. doi: 10.1002/wnan.1402 This article is categorized under: Diagnostic Tools > In Vivo Nanodiagnostics and Imaging Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease